Commonwealth Coat of Arms of Australia

 

PB 84 of 2024

 

National Health (Floor Price for Certain Brands of Pharmaceutical Items) Amendment Determination (No. 4) 2024

I, Nikolai Tsyganov, as delegate of the Minister for Health and Aged Care, make the following Determination.

Dated 23 October 2024    

Nikolai Tsyganov

Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Department of Health and Aged Care

Contents

1  Name

2  Commencement

3  Authority

4  Schedules

Schedule 1—Amendments—General

National Health (Floor Price for Certain Brands of Pharmaceutical Items) Determination 2023

Schedule 2—Amendments— Additional designated brands effective from 1 February 2025

National Health (Floor Price for Certain Brands of Pharmaceutical Items) Determination 2023

Schedule 3—Amendments— Additional designated brands effective from 1 April 2025

National Health (Floor Price for Certain Brands of Pharmaceutical Items) Determination 2023

 

 

1  Name

 (1) This instrument is the National Health (Floor Price for Certain Brands of Pharmaceutical Items) Amendment Determination (No. 4) 2024.

 (2) This instrument may also be cited as PB 84 of 2024.

2  Commencement

 (1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

 

Commencement information

Column 1

Column 2

Column 3

Provisions

Commencement

Date/Details

1.  Sections 1 to 4 and anything in this instrument not elsewhere covered by this table

The day after this instrument is registered.

 

2.  Schedule 1

The day after this instrument is registered.

 

3.  Schedule 2

1 February 2025.

1 February 2025

4.  Schedule 3

1 April 2025.

1 April 2025

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

 (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3  Authority

  This instrument is made under subsection 99ADHC(2) of the National Health Act 1953.

4  Schedules

  Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

 

Schedule 1Amendments—General

National Health (Floor Price for Certain Brands of Pharmaceutical Items) Determination 2023

1  Section 5 (table)

Omit:

Diltiazem AN

Diltiazem

Tablet containing diltiazem hydrochloride 60 mg

Oral

Schedule 2Amendments— Additional designated brands effective from 1 February 2025

National Health (Floor Price for Certain Brands of Pharmaceutical Items) Determination 2023

1  Section 5 (after table item dealing with the brand Isoleucine 50 of the drug Isoleucine with carbohydrate in the form Sachets of oral powder 4 g containing 50 mg isoleucine, 30 (Isoleucine 50))

Insert:

APO-Levetiracetam

Levetiracetam

Oral solution 100 mg per mL, 300 mL

Oral

Keppra

Levetiracetam

Oral solution 100 mg per mL, 300 mL

Oral

Kerron

Levetiracetam

Oral solution 100 mg per mL, 300 mL

Oral

Levetiracetam GH

Levetiracetam

Oral solution 100 mg per mL, 300 mL

Oral

Levetiracetam-AFT

Levetiracetam

Oral solution 100 mg per mL, 300 mL

Oral

APO-Levetiracetam

Levetiracetam

Tablet 1 g

Oral

Keppra

Levetiracetam

Tablet 1 g

Oral

Kevtam 1000

Levetiracetam

Tablet 1 g

Oral

Levactam

Levetiracetam

Tablet 1 g

Oral

Levetiracetam GH

Levetiracetam

Tablet 1 g

Oral

Levetiracetam Mylan

Levetiracetam

Tablet 1 g

Oral

Levetiracetam SZ

Levetiracetam

Tablet 1 g

Oral

Levetiracetam Viatris

Levetiracetam

Tablet 1 g

Oral

Levi 1000

Levetiracetam

Tablet 1 g

Oral

NOUMED LEVETIRACETAM

Levetiracetam

Tablet 1 g

Oral

 


Schedule 3Amendments— Additional designated brands effective from 1 April 2025

National Health (Floor Price for Certain Brands of Pharmaceutical Items) Determination 2023

1  Section 5 (before table item dealing with the brand GA gel of the drug Amino acid formula with vitamins and minerals without lysine and low in tryptophan in the form Sachets containing oral powder 24 g, 30 (GA gel))

Insert:

Fosamax Plus 70 mg/140 mcg

Alendronic acid with colecalciferol

Tablet 70 mg (as alendronate sodium) with 140 micrograms colecalciferol

Oral

Fosamax Plus

Alendronic acid with colecalciferol

Tablet 70 mg (as alendronate sodium) with 70 micrograms colecalciferol

Oral

2  Section 5 (after table item dealing with the brand Kineret of the drug Anakinra in the form Injection 100 mg in 0.67 mL single use pre-filled syringe)

Insert:

Atropine Injection (Pfizer)

Atropine

Injection containing atropine sulfate monohydrate 600 micrograms in 1 mL

Injection

Colazide

Balsalazide

Capsule containing balsalazide sodium 750 mg

Oral

3  Section 5 (after table item dealing with the brand Bicillin L-A of the drug Benzathine benzylpenicillin in the form Injection containing 600,000 units benzathine benzylpenicillin tetrahydrate in 1.17 mL single use pre-filled syringe)

Insert:

Lax-Tab

Bisacodyl

Tablet 5 mg

Oral

4  Section 5 (after table item dealing with the brand Pulmicort Turbuhaler of the drug Budesonide in the form Powder for oral inhalation in breath actuated device 200 micrograms per dose, 200 doses)

Insert:

Calci-Tab 600

Calcium

Tablet 600 mg (as carbonate)

Oral

5  Section 5 (after table item dealing with the brand Triumeq of the drug Dolutegravir with abacavir and lamivudine in the form Tablet containing dolutegravir 50 mg with abacavir 600 mg and lamivudine 300 mg)

Insert:

Mayne Pharma Erythromycin

Erythromycin

capsule 250 mg (containing enteric coated pellets)

Oral

6  Section 5 (after table item dealing with the brand Estraderm MX 25 of the drug Estradiol in the form Transdermal patches 750 micrograms (as hemihydrate), 8)

Insert:

Ferro-Liquid

Ferrous Sulfate

Oral liquid containing 30 mg ferrous sulfate heptahydrate per mL, 250 mL

Oral

7  Section 5 (after table item dealing with the brand Flucil of the drug Flucloxacillin in the form Powder for oral liquid 250 mg (as sodium monohydrate) per 5 mL, 100 mL)

Insert:

Lasix

Furosemide

Oral solution 10 mg per ml, 30 ml

Oral

8  Section 5 (after table item dealing with the brand Fucidin of the drug Fusidic acid in the form Tablet containing sodium fusidate 250 mg)

Insert:

Nitrolingual Pumpspray

Glyceryl trinitrate

Sublingual spray (pump pack) 400 micrograms per dose, 200 doses

Sublingual

9  Section 5 (after table item dealing with the brand Isoleucine 50 of the drug Isoleucine with carbohydrate in the form Sachets of oral powder 4 g containing 50 mg isoleucine, 30 (Isoleucine 50)

Insert:

Presolol 100

Labetalol

Tablet containing labetalol hydrochloride 100 mg

Oral

10  Section 5 (after table item dealing with the brand MORPHINE SULFATE 30 mg/1 mL MEDSURGE of the drug Morphine in the form Injection containing morphine sulfate pentahydrate 30 mg in 1 mL)

Insert:

Norimin-1 28 Day

Norethisterone with ethinylestradiol

Pack containing 21 tablets 1 mg-35 micrograms and 7 inert tablets

Oral

Norimin 28 Day

Norethisterone with ethinylestradiol

Pack containing 21 tablets 500 micrograms-35 micrograms and 7 inert tablets

Oral

11  Section 5 (after table item dealing with the brand Lipistart of the drug Triglycerides - medium chain, formula in the form Oral powder 400 g (Lipistart))

Insert:

MCT Oil

Triglycerides, medium chain

Oil 500 ml (MCT Oil)

Oral